SCHEMBL1668988

SCHEMBL1668988

CCCCCCCCCCCC1OCCO1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
EPHX1 P07099 1/20 0.58
SPHK1 Q9NYA1 7/20 0.46
SPHK2 Q9NRA0 6/20 0.46
PRKD3 O94806 2/20 0.44
PRKCG P05129 2/20 0.44
PRKCB P05771 2/20 0.44
PRKCA P17252 2/20 0.44
PRKCH P24723 2/20 0.44
PRKCI P41743 2/20 0.44
PRKCE Q02156 2/20 0.44
PRKCQ Q04759 2/20 0.44
PRKCZ Q05513 2/20 0.44
PRKCD Q05655 2/20 0.44
PRKD1 Q15139 2/20 0.44
TDP1 Q9NUW8 1/20 0.42
ENPP2 Q13822 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413367 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL16995925 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL28757032 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL873108 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL2102930 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL10514828 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL136872 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL14779258 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL15560286 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL27821359 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000048570-A1 PHARMACEUTICAL COMPOSITION FOR BALANIC TRANSMUCOSAL ADMINISTRATION OF ALFUZOSIN SANOFI-SYNTHELABO (FR) 2000-08-24 WO claimed
EP-0728462-A2 Cosmetic method and composition for treating hair loss MacroChem Corporation (US) 1996-08-28 EP claimed
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES Ananda Scientific, Inc. (US) 2025-06-19 US disclosed
US-20210330667-A1 TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME LUMOSA THERAPEUTICS CO., LTD. (TW) 2021-10-28 US disclosed
WO-2015051525-A1 SYNTHESIS OF ACETAL/KETAL RHODIA OPERATIONS (FR) 2015-04-16 WO disclosed
US-8916329-B2 Hardmask composition and associated methods CHEIL INDUSTRIES, INC. (KR) 2014-12-23 US disclosed
EP-2303265-B1 STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE GLENMARK PHARMACEUTICALS LTD (IN) 2014-12-10 EP disclosed
US-20110105448-A1 Stable Topical Formulation Comprising Voriconazole GLENMARK PHARMACEUTICALS LIMITED (IN) 2011-05-05 US disclosed
EP-2303265-A2 STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE Glenmark Pharmaceuticals Limited (IN) 2011-04-06 EP disclosed
WO-2010084505-A2 STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE GLENMARK PHARMACEUTICALS LIMITED (IN) 2010-07-29 WO disclosed
EP-1865896-A1 ENHANCEMENT OF MACROLIDE PENETRATION THROUGH HUMAN SKIN MacroChem Corporation (US) 2007-12-19 EP disclosed
WO-1999020257-A1 HORMONE REPLACEMENT THERAPY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN MACROCHEM CORPORATION (US) 1999-04-29 WO disclosed
EP-0552879-B1 Improved iontophoretic administration of drugs MACROCHEM CORP (US) 1998-08-19 EP disclosed
US-5620980-A TOPICALLY APPLYING MINOXIDIL AND PENETRATION ENHANCING AMOUNT OF 2-ALKYL-1,3-DIOXOLANE TO SKIN MACROCHEM CORPORATION (US) 1997-04-15 US disclosed
EP-0728462-A2 Cosmetic method and composition for treating hair loss MacroChem Corporation (US) 1996-08-28 EP disclosed
US-5527797-A IONTOPHORESIS MACROCHEM CORPORATION (US) 1996-06-18 US disclosed
EP-0552879-A1 Improved iontophoretic administration of drugs MACROCHEM CORPORATION (US) 1993-07-28 EP disclosed
EP-0268460-B1 NEW PERCUTANEOUS ABSORPTION ENHANCERS, COMPOSITIONS CONTAINING SAME AND METHOD OF USE Macrochem Corporation (US) 1991-11-06 EP disclosed
US-4861764-A Percutaneous absorption enhancers, compositions containing same and method of use MACRO CHEM. CORP. (US) 1989-08-29 US disclosed
EP-0268460-A1 New percutaneous absorption enhancers, compositions containing same and method of use Macrochem Corporation (US) 1988-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES CNR2, CNR1, FAAH ALDH1A1 1320/4885EPHX1 817/4885SPHK1 211/4885
US-20110105448-A1 Stable Topical Formulation Comprising Voriconazole ERG28, CYP51A1, PIK3C3 ALDH1A1 4022/4885EPHX1 3530/4885SPHK1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.